GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » Asset Turnover

Entrada Therapeutics (Entrada Therapeutics) Asset Turnover : 0.12 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Entrada Therapeutics's Revenue for the three months ended in Mar. 2024 was $59.1 Mil. Entrada Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $490.0 Mil. Therefore, Entrada Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.12.

Asset Turnover is linked to ROE % through Du Pont Formula. Entrada Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was 36.73%. It is also linked to ROA % through Du Pont Formula. Entrada Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was 19.18%.


Entrada Therapeutics Asset Turnover Historical Data

The historical data trend for Entrada Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entrada Therapeutics Asset Turnover Chart

Entrada Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - - 0.36

Entrada Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.04 0.09 0.09 0.12

Competitive Comparison of Entrada Therapeutics's Asset Turnover

For the Biotechnology subindustry, Entrada Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entrada Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Asset Turnover falls into.



Entrada Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Entrada Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=129.013/( (252.056+469.192)/ 2 )
=129.013/360.624
=0.36

Entrada Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=59.12/( (469.192+510.844)/ 2 )
=59.12/490.018
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Entrada Therapeutics  (NAS:TRDA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Entrada Therapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=93.984/255.8635
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(93.984 / 236.48)*(236.48 / 490.018)*(490.018/ 255.8635)
=Net Margin %*Asset Turnover*Equity Multiplier
=39.74 %*0.4826*1.9152
=ROA %*Equity Multiplier
=19.18 %*1.9152
=36.73 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Entrada Therapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=93.984/490.018
=(Net Income / Revenue)*(Revenue / Total Assets)
=(93.984 / 236.48)*(236.48 / 490.018)
=Net Margin %*Asset Turnover
=39.74 %*0.4826
=19.18 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Entrada Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Entrada Therapeutics (Entrada Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6 Tide Street, Boston, MA, USA, 02210
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Executives
Dipal Doshi director, officer: President and CEO C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Kory James Wentworth officer: Chief Financial Officer 6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Nathan J Dowden officer: Chief Operating Officer 6 TIDE STREET, BOSTON MA 02210
Nerissa Kreher officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman director C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Natarajan Sethuraman officer: Chief Scientific Officer 6 TIDE STREET, BOSTON MA 02210
Bernhardt G Zeiher director ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
John F Crowley director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142